ArticleWorld journal of surgical oncology2026
MiR-5100 promotes the malignant phenotype of triple-negative breast cancer cells by targeting SMAD4 and predicts poor prognosis.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is a notoriously aggressive subtype with poor prognosis. MicroRNAs (miRNAs) critically regulate epithelial-mesenchymal transition (EMT), a central driver of cancer metastasis. Nevertheless, the function of hsa-miR-5100 in TNBC was poorly understood. This study investigated the effects of miR-5100 on the malignant behaviors of TNBC cells, its correlation with patient prognosis, and underlying molecular mechanisms.
methodsPlasma levels of miR-5100 were assessed in a cohort of 80 TNBC patients and 80 healthy controls. Based on miR-5100 expression levels, patients were categorized into high and low groups, with 5-year survival as the primary endpoint for Kaplan-Meier and Cox regression analyses. MiR-5100 was assessed for its effects on proliferation, migration, invasion, and EMT in TNBC cell lines (MDA-MB-231 and MDA-MB-468), with its direct interaction with SMAD4 confirmed by dual-luciferase reporter assay.
resultsUpregulation of miR-5100 was observed in TNBC patients. Elevated miR-5100 levels correlated with advanced TNM stage, lymph node metastasis, high Ki-67 proliferation index, and reduced survival. Overexpression of miR-5100 promoted the proliferation, migration and invasion of TNBC cells. MiR-5100 overexpression mediated the reciprocal regulation of E-cadherin (down) and N-cadherin (up) at both mRNA and protein levels in TNBC cells. Mechanistically, the oncogenic effects of miR-5100 on TNBC cell proliferation, migration, invasion, and EMT were mediated through its direct targeting of SMAD4.
conclusionsMiR-5100 was upregulated in TNBC patients and was associated with a poor prognosis. By targeting SMAD4, miR-5100 promoted the malignant phenotypes of TNBC cells in vitro, suggesting its potential research value as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.